We have located links that may give you full text access.
Combined IL-2 and IL-12 gene therapy for murine head and neck squamous cell carcinoma.
OBJECTIVE: To evaluate the efficacy of combined interleukin (IL)-2 gene and IL-12 gene therapy in murine model with head and neck squamous cell carcinoma (HNSCC).
METHODS: HNSCC model was established in the mouth floor of C3H/HeJ mice with SCCVII cell line. Lipid-IL2 and lipid-IL12 plasmid complexes were introduced either alone or in combination into the tumor by direct intratumor gene injection. Tumor size was measured before and after the treatment to evaluate the response of the different treatment and control groups. Enzyme-linked immunosorbent assay (ELISA) was used to measure the IL-2 and IL-12 expression. Lactic dehydrogenase (LDH) assay was used to evaluate the activity of Cytotoxic T-Lymphocyte (CTL) and natural killer (NK) cells.
RESULTS: Growth of HNSCC was significantly inhibited in combined IL-2 and IL-12 gene therapy group as compared with the other groups (P < 0.01). Increased level of IL-2 and IL-12 protein expression was found in both combined and single treatment groups. Greater activity of CTL and NK was also observed in these two groups as compared with the controls.
CONCLUSION: Both IL-2 and IL-12 gene therapy is able to inhibit the growth of HNSCC and induce the host antitumor immune response efficiently in the murine model. Combination of the two in gene therapy may be additive or synergistic in antitumor effect.
METHODS: HNSCC model was established in the mouth floor of C3H/HeJ mice with SCCVII cell line. Lipid-IL2 and lipid-IL12 plasmid complexes were introduced either alone or in combination into the tumor by direct intratumor gene injection. Tumor size was measured before and after the treatment to evaluate the response of the different treatment and control groups. Enzyme-linked immunosorbent assay (ELISA) was used to measure the IL-2 and IL-12 expression. Lactic dehydrogenase (LDH) assay was used to evaluate the activity of Cytotoxic T-Lymphocyte (CTL) and natural killer (NK) cells.
RESULTS: Growth of HNSCC was significantly inhibited in combined IL-2 and IL-12 gene therapy group as compared with the other groups (P < 0.01). Increased level of IL-2 and IL-12 protein expression was found in both combined and single treatment groups. Greater activity of CTL and NK was also observed in these two groups as compared with the controls.
CONCLUSION: Both IL-2 and IL-12 gene therapy is able to inhibit the growth of HNSCC and induce the host antitumor immune response efficiently in the murine model. Combination of the two in gene therapy may be additive or synergistic in antitumor effect.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app